Reporting Manager
BIOTECHNOLOGY VALUE FUND L P
Symbol
ITOS
Disclosed Ownership
0 shares
Ownership
0%
Form type
SCHEDULE 13G/A
Filing time
14 Aug 2025, 16:03:53 UTC
Date of event
30 Jun 2025
Previous filing
15 May 2025

Sponsored

Quoteable Key Fact

"BIOTECHNOLOGY VALUE FUND L P disclosed 0% ownership in iTeos Therapeutics, Inc. Common Stock, $0.001 par value per share (ITOS) on 30 Jun 2025."

Quick Takeaways

  • BIOTECHNOLOGY VALUE FUND L P filed SCHEDULE 13G/A for iTeos Therapeutics, Inc. Common Stock, $0.001 par value per share (ITOS).
  • Disclosed ownership: 0%.
  • Date of event: 30 Jun 2025.

What Changed

  • Previous schedule filing date: 15 May 2025.
  • Current filing was accepted on 14 Aug 2025, 16:03.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Official SEC Source

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (10)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
BIOTECHNOLOGY VALUE FUND L P 0% 0 0 0 /s/ Mark N. Lampert Mark N. Lampert, Authorized Signatory
BVF I GP LLC 0% 0 0 0 /s/ Mark N. Lampert Mark N. Lampert, Authorized Signatory
BIOTECHNOLOGY VALUE FUND II LP 0% 0 0 0 /s/ Mark N. Lampert Mark N. Lampert, Authorized Signatory
BVF II GP LLC 0% 0 0 0 /s/ Mark N. Lampert Mark N. Lampert, Authorized Signatory
Biotechnology Value Trading Fund OS LP 0% 0 0 0 /s/ Mark N. Lampert Mark N. Lampert, Authorized Signatory
BVF Partners OS Ltd. 0% 0 0 0 /s/ Mark N. Lampert Mark N. Lampert, Authorized Signatory
BVF GP HOLDINGS LLC 0% 0 0 0 /s/ Mark N. Lampert Mark N. Lampert, Authorized Signatory
BVF PARTNERS L P/IL 0% 0 0 0 /s/ Mark N. Lampert Mark N. Lampert, Authorized Signatory
BVF INC/IL 0% 0 0 0 /s/ Mark N. Lampert Mark N. Lampert, Authorized Signatory
LAMPERT MARK N 0% 0 0 0 /s/ Mark N. Lampert Mark N. Lampert